List view / Grid view
8 November 2013 | By Pfizer
The primary endpoint of the study was not achieved as there was not a statistically significant difference in renal function improvement...
7 November 2013 | By Amgen
Innovative program - Amgen Biotech Experience - brings real-world biotechnology lab experience to students...
7 November 2013 | By Abbott
Similac is trying to meet that resource need with the launch of StrongMoms Español, a free program that provides Hispanic moms relevant, Spanish-language resources...
6 November 2013 | By kdm communications limited
Quotient Clinical – the pioneer of Translational Pharmaceutics™ – will be showcasing the benefits of its unique, integrated approach to formulation development...
4 November 2013 | By GlaxoSmithKline
The results showed that the two-dose schedule in girls aged 9 to 14 years old induced immune responses...
4 November 2013 | By B3C Group GmbH
The collaboration aims to identify drug leads that block the activity of a number of challenging cancer therapeutic targets....
4 November 2013 | By Roche
Roche will make an upfront payment of CHF 35 million to Polyphor as well as payments upon reaching certain development...
4 November 2013 | By Johnson & Johnson
The resolution includes total settlement amounts of approximately $2 billion to the federal government...
2 November 2013 | By Creston Health
“The VALENCE results demonstrate the high efficacy of a 24-week, sofosbuvir-based, interferon-free treatment regimen for genotype 3 HCV patients..."
2 November 2013 | By Boehringer Ingelheim
"These data are encouraging and reinforce the potential benefits of faldaprevir* as an effective treatment..."
2 November 2013 | By Portland Communications
"Mundipharma recognises the current economic environment and resulting budget constraints for healthcare systems..."
2 November 2013 | By Janssen R&D Ireland
“The breadth of simeprevir data presented at AASLD reinforce its potential as a treatment option..."
2 November 2013 | By Merck
Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied...
2 November 2013 | By Bristol-Myers Squibb Company
"We are pleased to be one step closer to bringing a potential new treatment option to the many people living with HCV..."
1 November 2013 | By Janssen
Janssen continues to undertake clinical studies with telaprevir to identify opportunities to serve specialized and hard-to-treat patients...
